A breakthrough in cancer treatment has shown the efficacy of a new vaccine.
The U.S. Food and Drug Administration has approved the first clinical trial to test the vaccine’s ability to treat the highly contagious form of the infection.
It is being hailed as a first step toward a vaccine that is safe, effective and cost-effective.
Lymphoma, which is also known as non-Hodgkin lymphoma, is one of the most common cancers in the world.
It affects about 4.2 million people in the U.K., 1.3 million in the United States and 1.2 millions in other countries.
The vaccine, which works by killing the immune system, has been developed by Merck.
It has been tested in several clinical trials in the last decade, but the FDA approval was the first major milestone.
A vaccine is designed to prevent an immune response from occurring in the first place.
It protects against the harmful proteins that are found in the virus, or antigen.
The antibodies that the immune systems produce protect the body against the virus’ harmful effects.
The FDA approved the vaccine on Thursday, the same day the agency approved Merck’s Phase 1 clinical trial, which will enroll more than 100 patients, including some with Hodgkin’s disease.
The agency also approved a second Phase 1 trial in the same year.
The Phase 2 trial is being conducted in Europe.
The Phase 1 trials in Europe were carried out in collaboration with the United Kingdom’s National Institute for Health Research.
Both trials are being conducted under the auspices of the European Medicines Agency, which has been in charge of approving and regulating the vaccines since 2015.
The European Medicine Agency approved the vaccines in April and May, respectively.
The two trials will start in Germany in 2018.
In the United Nations, the agency is also working on the approval of the vaccine for use in Africa.
The new vaccines are the first to be approved for use outside of Africa, and will be given to people who are already infected with the virus.
The WHO is working with scientists from around the world to try to create vaccines that can be delivered safely and efficiently.
The agency said it will also continue to develop new vaccines to help fight the pandemic, including a vaccine to treat lung cancer.
The vaccines are being developed by two companies: Merck and Sanofi Pasteur.
Sanofi Pasteir is a major global drugmaker that includes drugs for treating infections caused by the coronavirus, including influenza, pneumonia, malaria and HIV.
It also owns the vaccine and treatment drug, GSK-2, used in the vaccine.
Merck is working on a vaccine for the disease, which was discovered in the late 1980s.
The company is developing the vaccine in partnership with the University of Oxford.
Merck said the vaccine is safe and has been approved by the FDA for the treatment of lymphoma.
It said the trial will involve a total of more than 300 patients, with a 60 percent chance of success.
“The Merck-Sanofi vaccine will provide the first significant protection against Hodgkin lymphomas,” Merck said in a statement.
“We are extremely grateful to the FDA, the FDA advisory panel, and the NIH for their continued support in developing this vaccine,” the company said.